Kornimate/medical-research-clean huggingface dataset:
peripheral choroidal layer response

Conditions: Myopia

Summary: the study aims to examine how the vascular layer of the eyeball (choroidal layer) responds when part of the visual field is exposed to specially generated visual stimulus. the study goal will be accomplished by producing specific blur visual stimulus at a particular visual field position and measure any consistent thickness change pattern in the choroidal layer. we propose to test the hypothesis that regional changes in the choroidal thickness may be induced differently after short-term exposure to specific visual stimuli.


Eligibility criteria:
inclusion criteria: a person is eligible for inclusion in the study if he/she: * is between the ages of 18 and 40 yrs old * has normal best corrected visual acuity being 20/20 or better * has spherical refractive error between +1.00d and -6.00d. * is capable of fixating on the target. * has no prior ocular surgery. * has no ocular pathology except keratoconus. * can tolerate dilating eye drops exclusion criteria: a person will be excluded from the study if he/she: * does not fall within above mentioned age group. * has chronic or systemic eye disease that would interfere with pupil dilation via eye drops. * underwent ocular surgeries or history of ocular trauma * has shallow anterior chamber angle and/or glaucoma. * has clinically significant dry eye. * has signs of any choroidal or retinal pathology, and abnormalities in the visual pathway * has spherical refractive error that exceeds the limits outlined above. * has binocular anomalies (e.g. convergence insufficiency, strabismus, pseudo-myopia, amblyopia). * is an adult unable to consent * is an individual who is not yet adult (infants, children, teenagers) * is a pregnant woman * is a prisoner * is a student for whom you have direct access to/influence on grades * is an economically and/or educationally disadvantaged person
comparison of insulin detemir plus insulin aspart with insulin nph plus human soluble insulin in subjects with type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in europe and south america. the aim of this trial is to compare the glycaemic control of insulin detemir plus insulin aspart with that of insulin nph plus human soluble insulin in subjects with type 1 diabetes on a basal/bolus regimen.


Eligibility criteria:
inclusion criteria: * type 1 diabetes for at least 12 months * current treatment with any basal/bolus regimen or any biphasic insulin treatment for at least 6 months * bmi below or equal to 35 kg/m\^2 * hba1c below or equal to 12% exclusion criteria: * proliferative retinopathy or maculopathy requiring acute treatment * recurrent major hypoglycaemia that may interfere with trial participation (as judged by the investigator) * subjects with known hypoglycaemic unawareness as judged by the investigator
injection of corticoids for the treatment of acute sprains of the proximal interphalangeal joints of the fingers.

Conditions: Sprain

Summary: there is currently no real consensus on the optimal management of acute sprains of the proximal interphalangeal joint of the long fingers. the aim of this study is to assess the beneficial effect of an injection of corticosteroids for the treatment of this type of sprain (one single sub-cutaneous injection, in the acute phase). this treatment, if effective, might become the treatment of choice for these types of injuries, instead of a prolonged immobilization or a careful early mobilization.


Eligibility criteria:
inclusion criteria: * adults over 18 years old * type i and ii and iii of the eaton classification (except if fracture/luxation with more than 50% of the articular surface injured) * trauma of one articulation only * consultation within 2 weeks of trauma exclusion criteria: * patients under 18 years old and over 80 years old * pregnant/nursing women * eaton classification type ii with a fracture affecting more than 50% of the articular surface, or persistant instability after reduction. * open wounds, nerve lesion with sensitive issue and any wound needing a surgical intervention * underlying pathologies: rhumatological, neurological, congenital (giving hyperextensive articulations as a result) * corticoids allergy * infection within the treated zone * trauma antecedents at the level of the tendons.

Keywords: sprains of the proximal interphalangeal joints of the long fingers diprophos
comparison the effects of different neoadjuvant chemotherapy regimen on acute toxicity, tumor response, and survival in patients with advanced nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: the purpose of this study is to investigate the impact of different neoadjuvant chemotherapy schedules of cisplatin and 5-fu on acute toxicity, tumor response, and long-term survival in patients with advanced nasopharyngeal carcinoma

control group: neoadjuvant chemotherapy with tri-weekly pf × 3 cycles (cisplatin 100 mg/m2, day 1, followed by 5-fu 1000 mg/m2/d, days 1-4 continuous iv infusion, repeated every 3 weeks) + imrt ≧ 70 gy/35 fractions test group: neoadjuvant chemotherapy with weekly p-fl × 10 weeks (cisplatin 60 mg/m2 at days 1, 15, 29, 43, 57; alternatively with 5-fu 2500 mg/m2 + leucovorin 250 mg/m2 at days 8, 22, 36, 50, 64) + imrt ≧ 70 gy/35 fractions

Eligibility criteria:
inclusion criteria: 1. histological proven npc. 2. 2010 ajcc stage ii-ivb. 3. age ≧ 20 years old. 4. performance status of ecog ≦ 2. 5. adequate liver, renal, and bone marrow functions 5-1 serum total bilirubin level ≦ 2.5 mg/dl. 5-2 serum creatinine ≦ 1.6 mg/dl or calculated ccr ≧ 60 cc/min. 5-3 wbc ≧ 3,000/ul 5-4 platelet count ≧ 100,000/ul 6. signed informed consent. exclusion criteria: 1. presence of distant metastasis. 2. previous radiotherapy or chemotherapy. 3. history of a malignancy except those treated with curative intent for skin cancer (other than melanoma), in situ cervical cancer, ductal carcinoma in situ (dcis) of the breast. 4. severe cardiopulmonary diseases (unstable angina and/or congestive heart failure or peripheral vascular disease requiring hospitalization within the last 12 months; chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization) or clinically significant psychiatric disorders. 5. female patients who are pregnant or lactating.
low-intensity extracorporeal shockwave therapy and vacuum erectile device as a treatment for peyronies disease.

Conditions: Peyronie Disease

Summary: aim the primary aim is to examine whether li-eswt and vacuum erectile device (ved) followed by manipulation exercises has beneficial effect on pd patients compared to a placebo group. primary outcome * peyronie's disease questionnaire (pdq) * visual analogue scale score (vas) * international index of erectile function 5 (ieff-5) * penile curve measurements (gold standard) on pictures before and after treatment * plaque size method this study is designed as a prospective, randomized, double-blinded, placebo-controlled with follow-up after 1, 3 and 6 months. a total of 50 participants who meets the inclusion criteria's will randomly be assigned to i(intervention) or c(control) group based on a randomization list which is retained in a sealed envelope. the content of the envelope is only familiar to the head of the department of urology to ensure valid randomization. all treatment sessions are executed at the outpatient clinic of the department of urology department l at odense university hospital(ouh). all patients receive treatment with the same device a duolith® sd1 t-top from storz medical. however, when treating patients in the control group the handpiece will be covered by a shockwave absorbent material. settings and setup are identical in both groups to make sure that patients are unable to acknowledge which treatment is being performed.


Eligibility criteria:
inclusion criteria: * pd for more than 6 months * penile curve greater than 30 degrees and less than 90 degrees * age 18-80 * no previous penile surgery * informed consent * able to speak and understand danish exclusion criteria: * penile curve greater than 90 degrees * previous surgery for pd * patients undergoing other interventions for pd
improvement of appendix identification and appendicitis diagnosis in us after administration of oral contrast medium

Conditions: Appendicitis

Summary: rate of appendix localization on ultrasound is not high. we suggest a way to improve it's localization by oral administration of iodinated contrast material.

the administration of oral iodinated contrast material might facilitate identification of the appendix and accurate diagnosis of appendicitis. when indicated will shorten time to ct examination.

Eligibility criteria:
inclusion criteria: * patients in emergency department with right lower quadrant pain exclusion criteria: * patients under 18 years old * pregnant women

Keywords: ultrasound iodinated contrast material computed tomography
effects of nature exposure on smoking behavior

Conditions: Tobacco Smoking

Summary: smoking continues to be the leading cause of preventable death and disease in the u.s. while smoking is a significant threat to public health in the us in general, the negative effects of smoking disproportionately affect americans with 12 or fewer years of education and those living below the poverty line. given these health disparities, it is vital to have widely-available treatments that can be applied in multiple contexts in a cost-efficient way. while numerous methodologies and intervention programs exist, there is a need for improved cessation programs targeted to smokers with low levels of education attainment and income, as these smokers tend to be less likely to receive cessation assistance from a health care provider or have sufficient resources to access treatments. therefore, the present proposal aims to assess the feasibility of a tool that will improve smoking cessation programs in a short and cost-effective manner: a brief exposure to nature. the health and wellbeing benefits of nature exposure have been well researched and are widely recognized, and research on the underlying mechanism for nature's positive impact on health has identified a reduction in impulsivity as a mediator of this effect. however, this work has never been directly translated to smoking outcomes, and thus the translational purpose of the present project is to assess the feasibility of a brief and cost-effective nature exposure intervention on smoking cessation outcomes. prior work demonstrates the validity of the causal links in the nature -\> impulsivity -\> smoking cessation model. research has shown that nature exposure reduces impulsivity for health-related outcomes, and found that increased impulsivity is linked to all stages of smoking. a necessary step in developing a practical application for this research is the aim of the present project. smokers will be recruited online and randomly assigned to either the nature or control condition. participants in the nature condition will be given a nature-based intervention, while participants in the control condition will be given a non-nature-based intervention. participants will be contacted via text message throughout the following 24 hours and asked to report their degree of urgency to smoke and number of cigarettes smoked. participants will complete measurements of impulsivity, income, socio-economic status, and education, and additional smoking-related constructs.


Eligibility criteria:
inclusion criteria: * smoked at least two cigarettes per day for the last seven or more days * must be 18 years old or older * must have a smart cellular phone that can send and receive text messages and open web links exclusion criteria: -
cyclophosphamide plus topotecan in treating patients with refractory or relapsed acute myelogenous leukemia

Conditions: Leukemia

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of cyclophosphamide plus topotecan in treating patients who have refractory or relapsed acute myelogenous leukemia.

objectives: i. evaluate the efficacy of cyclophosphamide followed by topotecan in patients with relapsed or refractory acute myelogenous leukemia. ii. confirm safety and tolerability of this combination on this schedule in these patients. outline: patients receive cyclophosphamide intravenously over 1 hour on day 1 followed by topotecan as a continuous 120 hour infusion starting 12 hours after completion of cyclophosphamide. treatment may be repeated every 3-6 weeks for at least 2 courses. projected accrual: a total of 26 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically proven acute myelogenous leukemia by bone marrow aspirate or biopsy clear evidence of relapse or residual disease with greater than 5% blasts on bone marrow examination or greater than 30% peripheral blasts no active cns leukemia not eligible for potentially curative allogeneic or autologous bone marrow transplantation without further surgery must have failed to achieve a complete remission with conventional chemotherapy (cytarabine based) or have relapsed within 12 months after initial remission patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: at least 6 weeks hematopoietic: see disease characteristics hepatic: bilirubin less than 1.6 mg/dl (unless due to disease) renal: creatinine less than 1.6 mg/dl (unless due to disease) no prior hemorrhagic cystitis other: not pregnant fertile patients must use effective contraception no active uncontrolled infection prior concurrent therapy: biologic therapy: see disease characteristics chemotherapy: see disease characteristics recovered from prior chemotherapy no other concurrent chemotherapy endocrine therapy: not specified radiotherapy: must have recovered from prior radiotherapy surgery: not specified

Keywords: recurrent adult acute myeloid leukemia
study through imaging of visceral lymphoid organs in patients with scid who have recieved bone marrow allograft

Conditions: Severe Combined Immunodeficiency

Summary: to investigate the presence of seconday of lymphoid organs in patients who underwent allogenic hematopoietic stem cell transplantation 15 to 45 years ago. the goal aims to assess the development of seconday lymphoid organs given the fact that the absence of myeloablation these patients present a split chimerism between t lymphocytes and the other leucocytes. thus, they may not be able to generate seconday lymphoid organs. practically, whole body mri is being used to visualise and quantify both mediastinal and intraabdominal lymph nodes. delta will be compared with those obtained in healthy age-matched individuals. it is scheduled to include 15 patients and 15 controls.


Eligibility criteria:
inclusion criteria: * patients with scid transplanted 15-45 years ago exclusion criteria: * none
ocular rigidity and outflow facility in glaucomatous and normal eyes

Conditions: Glaucoma

Summary: ocular rigidity characterizes the relationship between pressure and volume changes in the human eye and is expressed as a macroscopic coefficient. outflow facility is a measure of the resistance of the conventional outflow pathway and represents a parameter that is of interest in glaucoma. difficulties in the measurement of ocular rigidity in the living human eye have limited our knowledge on this parameter. however, ocular biomechanics have been implicated in the pathogenesis of this disease. the aim of this study is to characterize the pressure volume relation and quantify ocular rigidity and outflow facility in glaucomatous and normal eyes. for this purpose, the investigators have recently developed a manometric method for the measurement of ocular rigidity and outflow facility.


Eligibility criteria:
inclusion criteria: * patients with primary open or pseudoexfoliation glaucoma that are undergoing cataract surgery * patients undergoing cataract surgery without evidence of other ocular disease. exclusion criteria: * evidence of any ocular disease, other than specified in the inclusion criteria * previous ophthalmic surgery or trauma * significant visual field defect (md\ 0.9).
collagen matrix with tunnel technique compared to ctg for the treatment of periodontal recessions

Conditions: Gingival Recession

Summary: the aim of this study is to compare the efficacy of dental root coverage using the tunnel technique with connective tissue graft (ctg) and the same technique with collagen matrix for treatment of multiple gingival recessions miller class i and ii. this study is a randomized-controlled clinical trial of 6 months duration.

according to the medical databases, there are limited randomized clinical trials comparing xenogenic collagen matrix and ctg used with the tunnel technique. the collagen matrix is a possible alternative to connective tissue graft. the purpose of this clinical study is to compare short-term (3-6 months) outcomes of a root coverage using the tunnel technique with the collagen matrix and the same technique with ctg for the treatment of multiple recessions miller class i and ii. twenty eight patients are enrolled in the study. patients in the test group are treated with xenogenic collagen matrix using the tunnel technique whereas patients in the control group with ctg. clinical recordings are obtained at baseline and after 3 and 6 months. the percentage of average recession coverage (arc) is evaluated after 3 and 6 months after the surgery.

Eligibility criteria:
inclusion criteria: * presence of minimum two adjacent periodontal recessions miller class i or ii and at least 2 mm recessions depth. exclusion criteria: * approximal plaque index (api) \> 15%, * sulcus bleeding index (sbi) \> 10%, * systemic diseases with compromised healing potential or infectious diseases, * untreated periodontal conditions, * pregnant and lactating females.

Keywords: gingival recession mucogingival surgery collagen matrix connective tissue graft tunnel technique
evaluation of a program to improve the life quality of elderly

Conditions: Elderly

Summary: older people belong to an age group that has been increasing in recent decades, leading to a progressive ageing of the population. with the aim of reducing the generational digital divide, the use of technology in retirement homes was proposed. to this end, virtual reality glasses were used to allow the visualization of an external virtual world and, subsequently, it was evaluated whether their application improved the quality of life of the elderly by reducing the difficulties they have in participating in recreational activities outside these centers. a prospective quasi-experimental longitudinal study was carried out in the centers belonging to the basic health area of valls, with a study period from may 2023 to march 2024. quality of life was measured using the ad hoc "escala de calidad de vida rivas-bordas".


Eligibility criteria:
inclusion criteria: * age 65 or older. * resident of a geriatric home in the valls area. * individuals with slight, moderate, fair, or total impairment of social resources, as assessed by the duke university center (1978) social resources scale (oars). exclusion criteria: * individuals with a history of frequent migraines or motion sickness. * individuals with moderate or severe cognitive impairment (≥ 5 errors on the abbreviated pfeiffer test). * inability to communicate in spanish and/or catalan. * individuals with advanced visual and/or hearing impairments.

Keywords: virtualreality quality of life elderly
nis to examine the effectiveness of tdc in patients with metastatic non-squamous nsclc and high-risk genetic alterations

Conditions: Non-squamous Metastatic Non-Small-Cell Lung Carcinoma

Summary: this prospective, multicenter, non-interventional study (nis) in germany aims to collect real-life data of patients with non-squamous (nsq) metastatic non-small cell lung cancer (mnsclc) (incl. large cell neuroendocrine carcinoma (lcnec) if considered nsclc-like by the treating physician) for whom 1st line treatment initiation with tremelimumab and durvalumab in combination with a platinum-based chemotherapy (tdc) according to marketing authorization was scheduled. the study aims to describe the effectiveness with respect to mutations in kirsten rat sarcoma viral oncogene homolog (kras), serine/threonine kinase 11 (stk11), kelch-like ech-associated protein 1 (keap1), and tumor protein p53 (tp53) as well as expression of thyroid transcription factor 1 (ttf-1) and programmed death-ligand 1 (pd-l1) in routine clinical practice. the generated data aims to deepen the understanding of optimal, biomarker-guided treatment strategies for nsq mnsclc in distinct subgroups with a high medical need.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years * decision to start first-line (1l) treatment with tdc according to the current smpcs * histologically or cytologically confirmed diagnosis of nsq mnsclc (incl. lcnec if considered nsclc-like by the treating physician) * treatment-naïve for metastatic disease * no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) alterations * molecular next generation sequencing (ngs) panel as per institutional standard has been initiated (including the following genes: kras, stk11, keap1, and tp53) * ttf-1 expression analysis has been initiated * pd-l1 expression analysis has been initiated * women of childbearing potential must use effective contraception during treatment with durvalumab and for at least 3 months after the last dose of durvalumab * ability to understand the study concept * provision of signed informed consent form in accordance with applicable local provisions exclusion criteria: * current participation in interventional clinical trials * contraindications according to current smpcs

Keywords: nsclc, mnsclc, kras, stk11, keap1, tp53, poseidon, tremelimumab, durvalumab
surgical outcomes of conventional hysterectomy or manipulator-assisted abdominal hysterectomy

Conditions: Gynecologic Disease

Summary: objective: the comparison of surgical outcomes conventional hysterectomy and manipulator-assisted hysterectomy study design: prospective randomized controlled trial. allocation to either group occurred via computer-generated random numbers. sequentially numbered, opaque envelopes were prepared according to randomization. the patients were unaware of whether they would undergo a conventional hysterectomy or manipulator-assisted abdominal hysterectomy for their surgical procedure. the research coordinator unveiled group assignments upon individual patient recruitment by opening the corresponding envelope. study population: inclusion criteria were patients aged 40-70 years who underwent hysterectomy for benign gynecological indications. primary outcomes: (1) operation time. secondary outcomes: (1) postoperative early pain (visual analog score (vas) at 6th and 24th hours of the surgery) (2) intraoperative complications, (3) postoperative complications


Eligibility criteria:
inclusion criteria: * inclusion criteria were patients aged 40-70 years who underwent hysterectomy for benign gynecological indications exclusion criteria: * exclusion criteria were patients with additional procedures such as urogynecologic procedures, history of abdominal surgery with midline incision, patients with suspected gynecologic malignancy, endometriosis, tubo-ovarian abscess, pelvic organ prolapse, or those who refused to participate in the study and whose medical records could not be obtained.

Keywords: hysterectomy, manipulator-assisted abdominal hysterectomy